Table 3. Results From RVV Selection Model (TSE-Pilot) for the Top 5 Criteria Ranked by Thai Stakeholders .
| Base-Case | ‘No Vaccine’ Scenario | |||||
| Size of birth cohort | 679 502 | |||||
| Total number of cases from 0-59 months | 337 596 | |||||
| Total hospitalizations | 50 054 | |||||
| Total deaths | 74 | |||||
| Total healthcare cost spent | 6.77 million USD | |||||
| Decision Criteria | Outcome Measures |
RVV-3
(Rank 1) |
RVV-2
(Rank 2) |
RVV-4
(Rank 3) |
RVV-5
(Rank 4) |
RVV-1
(Rank 5) |
| Safety | Number of intussusception cases | 4 | 11 | 3 | 5 | 19 |
| Health impact | Number of cases averted | 77 776 | 58 265 | 114 295 | 80 984 | 56 239 |
| Delivery costs | Delivery and storage costs (USD) | 8102 | 47 142 | 123 584 | 534 635 | 332 529 |
| Cost-effectiveness | ICER in comparison to no vaccine (USD/DALY averted) | 1254 | 1866 | 6830 | 7125 | 7113 |
| Budget impact | 5-year budget impact (million USD) | 8.83 | 9.57 | 65.76 | 48.55 | 30.37 |
Abbreviations: RVV, rotavirus vaccine; TSE, Total System Effectiveness; DALY, disability-adjusted life year; ICER, incremental cost-effectiveness ratio.